Skip to main content
SKYE logo

SKYE · Skye Bioscience, Inc.

Track SKYE — free
$1.02 -0.01 (-1.36%)
Market Cap
$4.56M
Shares
4.42M
Volume · Nov 19 12.7K Avg daily vol (62 sessions) 84.15K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.03 Open$1.00 Day$0.98–1.05 52W close$0.58–2.24 Avg vol 30d90K Short int129K · 2.9% of shares · 6.3d Short vol14% Last earningsMar 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 13

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CBeyond halted as Redx deal awaits conditions

Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.

Net income $69.13K Diluted EPS $0.01
Read from the MD&A section
4 source passages
In the second quarter of 2026, we terminated the CBeyond trial and paused all research and development activities for nimacimab. Unless otherwise provided in this Quarterly Report on Form 10-Q, references to “we,” “us,” “our” and “Skye” in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation, together with its consolidated subsidiaries. On August 14, 2026, we entered into the Transaction Agreement with Redx. Pursuant to the Transaction Agreement, and subject to the terms and conditions set forth therein, we will acquire the entire issued and to be issued share capital of Redx pursuant to a Scheme of Arrangement. The Financing is expected to provide the combined company with an aggregate total gross proceeds of approximately $103.9 million, which may increase to up to $108.9 million, subject to certain conditions set forth in the Side Letter. Open the document at this passage
Nov 12
Proxy statement DEFA14A
Jury returned unanimous verdict for company on all claims

Skye Bioscience, Inc. said a jury returned a unanimous verdict in its favor on all claims in the Wendy Cunning lawsuit on November 10, 2026. Judgment is expected in due course, but the plaintiff may file post-trial motions or appeal.

3 source passages
a former employee of the Company filed a lawsuit, entitled Wendy Cunning vs Skye Bioscience, Inc., in the U.S. District Court for the Central District of California On November 10, 2026, following the retrial in the District Court, the jury returned a unanimous verdict in favor of the Company on all claims. The Company expects the judgement by the District Court will be entered in due course. The plaintiff may file post-trial motions and may appeal any judgment entered on the verdict. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
Jury unanimously rules for Skye Bioscience on all claims

Skye Bioscience said a jury returned a unanimous verdict in its favor on all claims in former employee Wendy Cunning’s whistleblower and retaliation lawsuit on November 10, 2026. Judgment is expected soon, but post-trial motions or an appeal remain possible.

Other events
3 source passages
On November 10, 2026, following the retrial in the District Court, the jury returned a unanimous verdict in favor of the Company on all claims. The Company expects the judgement by the District Court will be entered in due course. The plaintiff may file post-trial motions and may appeal any judgment entered on the verdict. Open the document at this passage
Oct 26
Proxy statement PREM14A
Proxy statement

Skye Bioscience proposes acquiring Redx Pharma Limited, renaming the combined company Fibrx Therapeutics, Inc., and seeking stockholder approval for related share issuances, financing, charter amendments, compensation and meeting adjournment.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$37.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-671.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.78M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.9%
Latest settlement · 6.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg −31%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 27%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −37%
trailing
6-month return +6%
trailing
YTD return +37%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-28% holders QoQ · +8 funds added
Insider flow Distributing
Net -$304.3K over 90 days · 100% sells
Short interest Falling
2.92% of shares out · ▼ -7.8% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Weak
EPS growth −93%
Y/Y
Free cash flow $-43.1M
Balance sheet $5.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 264%
annualized · 1-yr
Max drawdown −69%
past year
ATR 17.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
−31% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
27% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-28% holders QoQ · +8 funds added
Insider flow Distributing
Net -$304.3K over 90 days · 100% sells
Short interest Falling
2.92% of shares out · ▼ -7.8% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 27% Range high $2
vs 200-day avg -1% vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SKYE
Skye Bioscience, Inc.
this stock
$4.56M — — — 2.9%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
31
% held
45.5%
Net QoQ
+10.8K sh
Top holder
5AM Venture Management, L…
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Falling
Shares short
129.3K
Days to cover
6.3d
Change
-11.0K sh
View
Short Volume
Short vol %
14%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
41
Value
$62
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
46.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$304.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-55.9M
EPS diluted
$-11.28
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
31

Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.

View
Proposed Sales
Value
$126.1K
Shares
22.9K
Filed
Nov 15, 2024
View
Exempt Offerings
Offering
$40.0M
Filed
Mar 27, 2024
View
Earnings & Events
Webcasts
Last webcast
Mar 10, 2026
View
Investor Relations
Latest news
Skye Bioscience and Redx Pharma A…
Published
Aug 14, 2026
View

Performance

5D 20D 120D MTD YTD
SKYE +12.1% -36.8% +6.2% -19.5% +37.4%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +16.0% -31.3% +9.7% -16.2% +30.3%
Key facts CIK 1516551 CUSIP 83086J309 13F (30d) 32 filings 29 filers Visit website Investor relations